Prime Minister Narendra Modi's mention of 'green jobs' in his Independence Day speech this year re-emphasised his commitment to achieving the Net Zero emissions target by 2070. The question is how will India, arguably the world's third-largest greenhouse gas emitter, achieve this target, with even the goal of limiting global warming to an increase of no more than 1.5 degrees Celsius (1.5°C) above pre-industrial levels, looking like a steep challenge?
As the market regulator, the Securities and Exchange Board of India (SEBI) has added heft to the net zero target, by expanding the disclosures that listed entities need to make related to Environmental, Social and Governance (ESG) factors.
A SEBI circular dated July 12, 2023 mandates that the top 150 listed entities (by market cap) had to undertake reasonable assurance of Business Responsibility and Sustainability Reporting (BRSR) Core from FY23-24, and this will extend to the top 1000 listed entities by FY26-27. The circular also requires the top 250 listed companies by market cap to disclose BRSR Core information for their value chain in their Annual Reports for FY24-25 on a comply-or-explain basis.
As Ramesh Swaminathan, Executive Director, Global CFO and Head of Corporate Affairs, Lupin points out, the pharmaindustry's contribution to the climate crisis comes from its 4.4 per cent share of global CO2 emissions. Although this percentage is lower than that of other industries, without action, emissions are expected to rise. Thus, he points out that the pharma industry has a unique responsibility to take action and promote sustainability. While it needs to reduce its greenhouse gas (GHG) emissions through net-zero strategies, it also needs to address the adverse health effects of the climate crisis by providing affordable medicines.
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Pharma's strategic path to growth in the nutra maze
The nutraceutical market is a thriving ecosystem of opportunities. For pharma companies, it's a space where the allure of a $11.55 billion pie by 2030 is tempered by a maze of regulatory grey zones, stiff competition, and trust-eroding marketing practices.
PRIME NEO from Gandhi Automations
Gandhi Automation's PRIME NEO High Speed Doors are designed to provide superior sealing and resistance to pressure differences for clean rooms. And the added advantage is that it is absolutely washable
AI smart camera for real-time automation
Integrated asset management functionality and a deep learning tool for training and evaluation keep productivity high and costs low
PROSOLV® 730: Directly compressible carrier for lipophilic ingredients
Nearly 90% of molecules in the discovery pipeline and 40% of drugs with market approval are poorly water soluble.
Complete environmental monitoring solution - testo Saveris Pharma
testo Saveris Pharma monitors and documents temperature, humidity, differential pressure, and other parameters without interruption and compliantly with GxP so that audits and inspections are conducted smoothly
The unmissable Asia healthcare opportunity
BCG's latest report, The Unmissable Asia Healthcare Opportunity, highlights the region's $5 trillion healthcare market potential by 2030, driven by demographic shifts, investment, and innovation.
2025: Healthcare and Lifesciences investment outlook
Kapil Khandelwal, Managing Partner, Toro Finserve and EquNev Capital, interprets the possibilities for the various segments of the Indian lifesciences and healthcare sector for this year
The group's offerings range from over a billion injection doses annually to bespoke medical machinery
Rishad Dadachanji, MD, Dadachanji Group speaks on the company's evolution from a pharma packaging company to a diversified solutions provider in biotechnology, automation, and sterile processing.
DECODING THE M&A LANDSCAPE
Consolidation has emerged as a major trend as the pharma industry seeks new avenues of growth and looks to expand its existing capabilities.
Evolution and commercialisation of cell and gene therapies
Satyen Sanghavi, Founder & CSO, Regrow Biosciences traces the evolution of cell and gene therapies, highlighting global milestones, industry growth, and reimbursement models.
